AioCare Respiratory Disease Management System
AioCare Respiratory Disease Management System
AioCare is a professional system to monitor and treat pulmonary diseases, consisting of a portable hospital-grade spirometer connected to a smartphone app and an online panel to access the results. The device enables a full spirometry test to be conducted in a doctor’s office, including a bronchial challenge workflow. If monitoring needs to go beyond the healthcare system, AioCare may be used for patients at home.
Please note, all products, services, or features of products and services may not be available in your local area. Please check with your local Vyaire representative. The information provided in this site is intended for healthcare professionals.
Use your AioCare spirometer for all essential spirometry testing: Flow/Volume-loop (FVC), Slow Vital Capacity (SVC), Pre and Post medication testing or therapy control.
Protect patients, staff and device from cross contamination by using the MicroGardTM II in-line filter.
MicroGard II filters provide 99.999% viral and bacterial efficiency against cross contamination (Nelson Test Report 1003754).
The AioCare doctor app has a smart integrated bronchodilator test workflow, offering step-by-step guidance. The algorithm behind is developed to guide primary care physicians in proofing the diagnosis of pulmonary diseases with obstruction reversibility testing.
AioCare can be used without any cable. The used smartphone, equipped with the AioCare app, is connected via secure Bluetooth. The data can be transferred to your practice or hospital system using SSL secured data transfers (API (REST), HIS (Hl7), SentrySuiteTM software).
The Latest News
Vyaire Medical Advances Surgical Sedation Safety with Novel Airway Technology for All Patient Risk Levels
October 29, 2021
Vyaire Medical Advances the Standard of Care in Low-Flow Oxygen Delivery
July 28, 2021
Vyaire Medical Debuts New Corporate Brand Affirming Commitment to Innovation that Enhances Quality of Breathing
April 14, 2021
Vyaire CEO Speaks with McKinsey about Company’s COVID-19 Response
April 12, 2021